Halozyme Therapeutics Inc. [HALO] stock is trading at $58.16, up 2.68%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HALO shares have gain 4.10% over the last week, with a monthly amount drifted -5.00%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Halozyme Therapeutics Inc. [NASDAQ: HALO] stock has seen the most recent analyst activity on September 19, 2024, when JP Morgan downgraded its rating to a Neutral and also boosted its price target to $57 from $52. Previously, Piper Sandler downgraded its rating to Neutral on June 07, 2024, and elevated its price target to $51. On February 29, 2024, TD Cowen initiated with a Outperform rating and assigned a price target of $54 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $61 on July 24, 2023. Goldman downgraded its rating to a Neutral and raised its price target to $45 on July 24, 2023. Piper Sandler upgraded its rating to Overweight for this stock on May 10, 2023, but kept the price target unchanged to $46.
Halozyme Therapeutics Inc. [HALO] stock has fluctuated between $32.83 and $65.53 over the past year. Currently, Wall Street analysts expect the stock to reach $56.86 within the next 12 months. Halozyme Therapeutics Inc. [NASDAQ: HALO] shares were valued at $58.16 at the most recent close of the market. An investor can expect a potential drop of -2.24% based on the average HALO price forecast.
Analyzing the HALO fundamentals
Halozyme Therapeutics Inc. [NASDAQ:HALO] reported sales of 873.30M for the trailing twelve months, which represents a growth of 4.67%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at 0.46%, Pretax Profit Margin comes in at 0.48%, and Net Profit Margin reading is 0.39%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 1.69 and Total Capital is 0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of5.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 56.78 points at the first support level, and at 55.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.97, and for the 2nd resistance point, it is at 59.77.
Ratios To Look Out For
For context, Halozyme Therapeutics Inc.’s Current Ratio is 7.41. In addition, the Quick Ratio stands at 6.21 and the Cash Ratio stands at 1.41. Considering the valuation of this stock, the price to sales ratio is 8.44, the price to book ratio is 25.43 and price to earnings (TTM) ratio is 22.55.
Transactions by insiders
Recent insider trading involved Torley Helen, PRESIDENT AND CEO, that happened on Sep 24 ’24 when 10000.0 shares were sold. PRESIDENT AND CEO, Torley Helen completed a deal on Sep 25 ’24 to sell 10000.0 shares. Meanwhile, PRESIDENT AND CEO Torley Helen sold 10000.0 shares on Sep 26 ’24.
